SUPPLEMENTARY FINANCIAL DATA (UNAUDITED) (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended								12 Months Ended
	Feb. 28, 2018	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Total revenue		$ 14,946	$ 13,194	$ 12,914	$ 14,257	$ 18,730	$ 18,257	$ 15,008	$ 19,862	$ 55,311	$ 71,857	$ 73,414
Costs and expenses		71,113	66,809	77,024	98,149	95,220	94,872	87,184	92,338	313,095	369,614	325,329
Loss from operations		(56,167)	(53,615)	(64,110)	(83,892)	(76,490)	(76,615)	(72,176)	(72,476)	(257,784)	(297,757)	(251,915)
Net loss		$ (32,034)	$ (35,308)	$ (52,405)	$ (79,679)	$ (58,434)	$ (73,643)	$ (62,887)	$ (83,053)	$ (199,426)	$ (278,017)	$ (236,455)
Basic net loss per share		$ (0.43)	$ (0.48)	$ (0.80)	$ (1.24)	$ (0.92)	$ (1.16)	$ (1.00)	$ (1.40)	$ (2.87)	$ (4.46)	$ (4.25)
Diluted net loss per share		$ (0.43)	$ (0.48)	$ (0.80)	$ (1.24)	$ (0.92)	$ (1.16)	$ (1.00)	$ (1.40)	$ (2.87)	$ (4.46)	$ (4.25)
Percentage of profit share	33.00%									35.00%
YUPELRI Monotherapy
Total revenue		$ 15,344	$ 13,806	$ 14,621	$ 12,908	$ 13,550	$ 12,960	$ 10,589	$ 12,880
Percentage of Net Sales										35.00%
Mylan
Percentage of profit share										65.00%